![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CORGENTECH FILES IND APPLICATION TO BEGIN PHASE I/II TRIAL OF NEW DRUG CANDIDATE FOR ECZEMA
CORGENTECH FILES IND APPLICATION TO BEGIN PHASE I/II TRIAL OF NEW DRUG CANDIDATE FOR ECZEMA
Corgentech has filed an investigational new drug application with the FDA to begin a Phase I/II clinical trial of its NF-kappaB Decoy (NF-kB Decoy) drug candidate for the treatment of atopic dermatitis, a chronic skin disease also known as eczema.
This is the first of two Phase I/II trials to be initiated. The second trial will be conducted in Europe and is expected to be initiated in the first half of 2005 in a similar patient population. The multicenter, randomized, double-blind, dose-ranging trial will evaluate the safety and feasibility of repeated application of three concentrations of NF-kB Decoy in adult patients with mild-to-moderate eczema.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct